Company intelligence / Profile preview

Unlearn

San Francisco, California, United Statesunlearn.ai ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Unlearn’s AI-powered digital twin technology is qualified by the European Medicines Agency for use as the primary analysis in phase 2 and 3 clinical trials with continuous outcomes. The company partners with leading pharmaceutical companies to accelerate trial timelines by reducing control arm size using simulated patient data. No direct drug development or clinical results; impact is measured via improved trial efficiency.

Therapeutic areas: ImmunologyNeurologyMetabolic Disorders
Modalities: Non-pharmacological therapySoftware platform
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

remynd (Alzheimer's study)Trace Neuroscience (ALS trial optimization)Multiple undisclosed global pharmaceutical companies

Beyond the preview

Go deeper on Unlearn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unlearn.

Explore the full profile